Allworth Financial LP Supernus Pharmaceuticals, Inc. Transaction History
Allworth Financial LP
- $17.4 Billion
- Q1 2025
A detailed history of Allworth Financial LP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 44 shares of SUPN stock, worth $1,429. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44
Previous 57
22.81%
Holding current value
$1,429
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
300Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$338 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$200 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$157 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$93.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$85.4 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.74B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...